Physician profile
Billy R Smith
NPI 1346275260
$9,620.69
in general payments reported to CMS, 2019-2025
41 companies · $364 in 2025
The $364 reported for 2025 was more than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,688 · 2020: $1,306 · 2021: $2,020 · 2022: $1,423 · 2023: $1,682 · 2024: $1,138 · 2025: $364.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,184.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $1,939.21 | 2019-2025 | Xtampza, Belbuca, Nucynta |
| Forte Bio-Pharma LLC | $1,514.45 | 2019-2024 | Prolate, Nalocet |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $887.89 | 2019-2025 | Relistor |
| Scilex Pharmaceuticals INC. | $742.02 | 2019-2024 | Ztlido |
| Abbvie INC. | $574.24 | 2021-2024 | Ubrelvy, Qulipta |
| Redhill Biopharma INC. | $387.63 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $290.09 | 2019-2023 | Ajovy |
| Valinor Pharma, LLC | $275.29 | 2023-2025 | Movantik |
| Indivior INC. | $267.63 | 2019-2025 | Sublocade |
| Daiichi Sankyo INC. | $253.13 | 2019 | |
| Pfizer INC. | $243.25 | 2019-2023 | |
| Braeburn INC. | $196.18 | 2024-2025 | Brixadi |
| Lilly USA, LLC | $186.67 | 2020-2025 | Zepbound, Mounjaro, Emgality |
| Biodelivery Sciences International, INC. | $181.93 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $167.30 | 2022 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Billy Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.